Cargando…

P912: ADDING REFRACTORINESS STATUS TO LINES OF THERAPY BETTER DEFINE PROGNOSIS OF A REAL LIFE ITALIAN MULTIPLE MYELOMA POPULATION

Detalles Bibliográficos
Autores principales:	More’, Sonia, Corvatta, Laura, Maria Manieri, Valentina, Morsia, Erika, Olivieri, Attilio, Offidani, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431153/ http://dx.doi.org/10.1097/01.HS9.0000970552.24750.d2

Ejemplares similares

P973: ATTRITION PROBABILITY AND PREDICTORS AMONG MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN HAEMATOLOGICAL TERTIARY CARE CENTRE
por: More’, Sonia, et al.
Publicado: (2023)

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2023)

Current Main Topics in Multiple Myeloma
por: Morè, Sonia, et al.
Publicado: (2023)

P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
por: Morè, S, et al.
Publicado: (2022)

P47 REAL-WORLD DATA OF ATTRITION RATES BY SUBSEQUENT LINES OF THERAPY IN MULTIPLE MYELOMA PATIENTS TREATED IN A TERTIARY CARE ITALIAN CENTRE
por: Morè, S., et al.
Publicado: (2023)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2020)

Novel Experimental Drugs for Treatment of Multiple Myeloma
por: Offidani, Massimo, et al.
Publicado: (2021)

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
por: Offidani, Massimo, et al.
Publicado: (2021)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
por: Morè, Sonia, et al.
Publicado: (2022)

PB2024: PREVALENCE OF TYPE 1 GAUCHER DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: FIRST INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY
por: Offidani, M., et al.
Publicado: (2022)

Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
por: Morè, Sonia, et al.
Publicado: (2023)

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
por: Offidani, Massimo, et al.
Publicado: (2014)

40 912 km
Publicado: (2020)

P912: COVID19 SEVERITY AND THERAPEUTIC OPTIONS IN PATIENTS WITH MULTIPLE MYELOMA
por: Karimova, E., et al.
Publicado: (2022)

Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications
por: Morsia, Erika, et al.
Publicado: (2022)

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
por: Offidani, M, et al.
Publicado: (2013)

Transcriptional profiles define drug refractory disease in myeloma
por: Zhu, Yuan Xiao, et al.
Publicado: (2022)

Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary “Real Life” Experience
por: Rupoli, Serena, et al.
Publicado: (2021)

PB2189: UNUSUAL SITE THROMBOSIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE EXPERIENCE WITH 66 CONSECUTIVE CASES.
por: Morsia, Erika, et al.
Publicado: (2023)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

A rare case of aCML associated with CNS involvement and with aggressive clinical course
por: Lame, Dorela, et al.
Publicado: (2023)

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
por: Goel, Utkarsh, et al.
Publicado: (2023)

Effect of 9,12-Octadecadiynoic Acid on Neurobehavioral Development in Caenorhabditis elegans
por: Chen, Tun-Chieh, et al.
Publicado: (2021)

912. Influence of a Global Pandemic on Bronchiolitis at a Bronx Hospital
por: Rosenberg, Michael, et al.
Publicado: (2023)

P1109: EPIDEMIOLOGY OF CUTANEOUS T-CELL LYMPHOMAS: DATA ANALYSIS FROM THE MARCHE MULTIDISCIPLINARY TEAM (MDT) REGISTER.
por: Morsia, Erika, et al.
Publicado: (2023)

Production of sigmao in sqrt (s) = 91.2 GeV qqbar events at LEP
por: Legan, Christopher Kenneth
Publicado: (1997)

912. Expansion of Hepatitis C Treatment with New Medicaid Subscription Model in Louisiana
por: Richey, Lauren E, et al.
Publicado: (2021)

MON-912 Undiagnosed Chronic Eczema as a Presentation of Glucagonoma in MEN 1 Syndrome
por: Dejhansathit, Siroj, et al.
Publicado: (2020)

POS-912 EFFECTIVENESS OF SARS-COV 2 VACCINATION IN KIDNEY TRANSPLANT PATIENTS IN CHILE
por: Pefaur Penna, J., et al.
Publicado: (2022)

P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY
por: Offidani, M., et al.
Publicado: (2023)

Production of gamma-aminobutyric acid by Lactobacillus brevis NCL912 using fed-batch fermentation
por: Li, Haixing, et al.
Publicado: (2010)

Behaviour of Cold Bore II during R 911 (28.2.78) and R 912
por: Benvenuti, C, et al.
Publicado: (1978)

Substrate sustained release-based high efficacy biosynthesis of GABA by Lactobacillus brevis NCL912
por: Wang, Qiong, et al.
Publicado: (2018)

SUN-912 The Rare Men of Mississippi Complications in the Diagnosis of Multiple Endocrine Neoplasia Type 1
por: Rashid, Hytham, et al.
Publicado: (2020)

912. Impact of Rapid Identification and Stewardship Intervention on Coagulase-negative Staphylococcus Bloodstream Infection (BSI)
por: Goshorn, Eli S, et al.
Publicado: (2022)

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma
por: Lecat, Catherine S. Y., et al.
Publicado: (2021)

912 Assessment of Automated Surveillance Strategies to Identify Infectious Complications Following Implanted Cardiac Device Procedures
por: Boggan, Joel C., et al.
Publicado: (2014)

912. Beyond the Usual Suspects in Invasive Mold Infections: Public Health Surveillance Identifies Clinical Diversity
por: Beer, Karlyn, et al.
Publicado: (2020)

A dual-task gait test detects mild cognitive impairment with a specificity of 91.2%
por: Wang, Yuxin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ti0tgfndd6mv3k5nc2gk33pnm8